Publications

1. Yoon H, Triplet EM, Wurtz L, Simon WL, Choi CI, Scarisbrick IA. Regulation of CNS Lipids by Protease Activated Receptor 1. J Neurochem. 2025 Mar; 169 (3):e70047
   View PubMed
2. Buchl SC, Kim HN, Hur B, Simon WL, Langley MR, Sung J, Scarisbrick IA. Delayed atorvastatin delivery promotes recovery after experimental spinal cord injury. Neurotherapeutics. 2025 Mar; 22 (2):e00517 Epub 2025 Jan 04
   View PubMed
3. Wurtz LI, Knyazhanskaya E, Sohaei D, Prassas I, Pittock S, Willrich MAV, Saadeh R, Gupta R, Atkinson HJ, Grill D, Stengelin M, Thebault S, Freedman MS, Diamandis EP, Scarisbrick IA. Identification of brain-enriched proteins in CSF as biomarkers of relapsing remitting multiple sclerosis. Clin Proteomics. 2024 Jun 16; 21 (1):42 Epub 2024 June 16
   View PubMed
4. Scarisbrick IA. PARting Neuroinflammation with Protease-Activated Receptor 2 Pepducins. J Pharmacol Exp Ther 2024 Jan 2; 388 (1):8-11 Epub 2024 Jan 02
   View PubMed
5. Sohaei D, Thebault S, Avery LM, Batruch I, Lam B, Xu W, Saadeh RS, Scarisbrick IA, Diamandis EP, Prassas I, Freedman MS. Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clin Proteomics. 2023 Aug 29; 20 (1):33
   View PubMed
6. Ulndreaj A, Sohaei D, Thebault S, Pons-Belda OD, Fernandez-Uriarte A, Campbell C, Cheo D, Stengelin M, Sigal G, Freedman MS, Scarisbrick IA, Prassas I, Diamandis EP. Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay. Diagnosis (Berl). 2023 Aug 1; 10 (3):275-280 Epub 2023 Feb 15
   View PubMed
7. Blaber AP, Sadeghian F, Naz Divsalar D, Scarisbrick IA. Elevated biomarkers of neural injury in older adults following head-down bed rest: links to cardio-postural deconditioning with spaceflight and aging. Front Hum Neurosci. 2023; 17:1208273 Epub 2023 Sept 26
   View PubMed
8. Yoon H, Triplet EM, Simon WL, Choi CI, Kleppe LS, De Vita E, Miller AK, Scarisbrick IA. Blocking Kallikrein 6 promotes developmental myelination. Glia. 2022 Mar; 70 (3):430-450 Epub 2021 Oct 09
   View PubMed
9. Langley MR, Choi CI, Peclat TR, Guo Y, Simon WL, Yoon H, Kleppe L, Lucchinetti CF, Chini CCS, Chini EN, Scarisbrick IA. Critical Role of Astrocyte NAD+ Glycohydrolase in Myelin Injury and Regeneration. J Neurosci. 2021 Oct 13; 41(41):8644-8667. Epub 2021 Sep 07.
   View PubMed
10. Kim HN, Triplet EM, Radulovic M, Bouchal S, Kleppe LS, Simon WL, Yoon H, Scarisbrick IA. The thrombin receptor modulates astroglia-neuron trophic coupling and neural repair after spinal cord injury. Glia. 2021 Sep; 69 (9):2111-2132 Epub 2021 Apr 22
    View PubMed
11. Triplet EM, Kim HN, Yoon H, Radulovic M, Kleppe L, Simon WL, Choi CI, Walsh PJ, Dutton JR, Scarisbrick IA. The thrombin receptor links brain derived neurotrophic factor to neuron cholesterol production, resiliency and repair after spinal cord injury. Neurobiol Dis. 2021 May; 152:105294 Epub 2021 Feb 05
    View PubMed
12. Triplet EM, Scarisbrick IA. Statin use is associated with reduced motor recovery after spinal cord injury. Spinal Cord Ser Cases. 2021 Feb 3; 7 (1):8 Epub 2021 Feb 03
    View PubMed
13. Langley MR, Triplet EM, Scarisbrick IA. Dietary influence on central nervous system myelin production, injury, and regeneration. Biochim Biophys Acta Mol Basis Dis. 2020 Jul 1; 1866 (7):165779 Epub 2020 Mar 26
    View PubMed
14. Kim HN, Langley MR, Simon WL, Yoon H, Kleppe L, Lanza IR, LeBrasseur NK, Matveyenko A, Scarisbrick IA. A Western diet impairs CNS energy homeostasis and recovery after spinal cord injury: Link to astrocyte metabolism. Neurobiol Dis. 2020 Jul; 141:104934 Epub 2020 May 04
    View PubMed
15. Langley MR, Yoon H, Kim HN, Choi CI, Simon W, Kleppe L, Lanza IR, LeBrasseur NK, Matveyenko A, Scarisbrick IA. High fat diet consumption results in mitochondrial dysfunction, oxidative stress, and oligodendrocyte loss in the central nervous system. Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1; 1866 (3):165630 Epub 2019 Dec 06
    View PubMed
16. Yoon H, Choi CI, Triplet EM, Langley MR, Kleppe LS, Kim HN, Simon WL, Scarisbrick IA. Blocking the Thrombin Receptor Promotes Repair of Demyelinated Lesions in the Adult Brain. J Neurosci. 2020 Feb 12; 40 (7):1483-1500 Epub 2020 Jan 07
    View PubMed
17. Wang Y, Hoeppner LH, Angom RS, Wang E, Dutta S, Doeppler HR, Wang F, Shen T, Scarisbrick IA, Guha S, Storz P, Bhattacharya R, Mukhopadhyay D. Protein kinase D up-regulates transcription of VEGF receptor-2 in endothelial cells by suppressing nuclear localization of the transcription factor AP2beta. J Biol Chem. 2019 Oct 25; 294 (43):15759-15767 Epub 2019 Sept 06
    View PubMed
18. Eftekhari R, de Lima SG, Liu Y, Mihara K, Saifeddine M, Noorbakhsh F, Scarisbrick IA, Hollenberg MD. Microenvironment proteinases, proteinase-activated receptor regulation, cancer and inflammation. Biol Chem. 2018 Sep 25; 399 (9):1023-1039
    View PubMed
19. Yoon H, Radulovic M, Scarisbrick IA. Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms. Biol Chem. 2018 Sep 25; 399 (9):1041-1052
    View PubMed
20. Choi CI, Yoon H, Drucker KL, Langley MR, Kleppe L, Scarisbrick IA. The Thrombin Receptor Restricts Subventricular Zone Neural Stem Cell Expansion and Differentiation. Sci Rep. 2018 Jun 19; 8 (1):9360 Epub 2018 June 19
    View PubMed
21. Yoon H, Radulovic M, Walters G, Paulsen AR, Drucker K, Starski P, Wu J, Wu J, Fairlie DP, Scarisbrick IA. Protease activated receptor 2 controls myelin development, resiliency and repair. Glia. 2017 Dec; 65 (12):2070-2086 Epub 2017 Sept 18
    View PubMed
22. Yoon H, Walters G, Paulsen AR, Scarisbrick IA. Astrocyte heterogeneity across the brain and spinal cord occurs developmentally, in adulthood and in response to demyelination. PLoS One. 2017; 12 (7):e0180697 Epub 2017 July 10
    View PubMed
23. Choi CI, Yoo KH, Hussaini SM, Jeon BT, Welby J, Gan H, Scarisbrick IA, Zhang Z, Baker DJ, van Deursen JM, Rodriguez M, Jang MH. The progeroid gene BubR1 regulates axon myelination and motor function. Aging (Albany NY). 2016 Sep 12; 8 (11):2667-2688
    View PubMed
24. Radulovic M, Yoon H, Wu J, Mustafa K, Scarisbrick IA. Targeting the thrombin receptor modulates inflammation and astrogliosis to improve recovery after spinal cord injury. Neurobiol Dis. 2016 Sep; 93:226-42 Epub 2016 May 01
    View PubMed
25. Yoon H, Kleven A, Paulsen A, Kleppe L, Wu J, Wu J, Ying Z, Gomez-Pinilla F, Scarisbrick IA. Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system. Biochim Biophys Acta. 2016 Apr; 1862 (4):545-555 Epub 2016 Jan 26
    View PubMed
26. Yoon H, Scarisbrick IA. Kallikrein-related peptidase 6 exacerbates disease in an autoimmune model of multiple sclerosis Biological Chemistry. 2016; 397(12):1277-86. Epub 1900 Jan 01.
    
27. Radulovic M, Yoon H, Wu J, Mustafa K, Fehlings MG, Scarisbrick IA. Genetic targeting of protease activated receptor 2 reduces inflammatory astrogliosis and improves recovery of function after spinal cord injury. Neurobiol Dis. 2015 Nov; 83:75-89 Epub 2015 Aug 24
    View PubMed
28. Drucker KL, Gianinni C, Decker PA, Diamandis EP, Scarisbrick IA. Prognostic significance of multiple kallikreins in high-grade astrocytoma. BMC Cancer. 2015 Aug 1; 15:565 Epub 2015 Aug 01
    View PubMed
29. Yoon H, Radulovic M, Drucker KL, Wu J, Scarisbrick IA. The thrombin receptor is a critical extracellular switch controlling myelination. Glia. 2015 May; 63 (5):846-59 Epub 2015 Jan 27
    View PubMed
30. Panos M, Christophi GP, Rodriguez M, Scarisbrick IA. Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response. Biol Chem. 2014 Sep; 395(9):1063-73.
    View PubMed
31. Radulovic M, Yoon H, Larson N, Wu J, Linbo R, Burda JE, Diamandis EP, Blaber SI, Blaber M, Fehlings MG, Scarisbrick IA. Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration. J Neuropathol Exp Neurol. 2013 Nov; 72 (11):1072-89
    View PubMed
32. Yoon H, Radulovic M, Wu J, Blaber SI, Blaber M, Fehlings MG, Scarisbrick IA. Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity. J Neurochem. 2013 Oct; 127 (2):283-98 Epub 2013 May 27
    View PubMed
33. Burda JE, Radulovic M, Yoon H, Scarisbrick IA. Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy. Glia. 2013 Sep; 61 (9):1456-70 Epub 2013 July 08
    View PubMed
34. Drucker KL, Paulsen AR, Giannini C, Decker PA, Blaber SI, Blaber M, Uhm JH, O'Neill BP, Jenkins RB, Scarisbrick IA. Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma. Neuro Oncol. 2013 Mar; 15 (3):305-18 Epub 2013 Jan 10
    View PubMed
35. Yoon H, Blaber SI, Li W, Scarisbrick IA, Blaber M. Activation profiles of human kallikrein-related peptidases by matrix metalloproteinases. Biol Chem. 2013 Jan; 394(1):137-47.
    View PubMed
36. Scarisbrick IA, Yoon H, Panos M, Larson N, Blaber SI, Blaber M, Rodriguez M. Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis. Brain Pathol. 2012 Sep; 22 (5):709-22 Epub 2012 Mar 21
    View PubMed
37. Scarisbrick IA, Radulovic M, Burda JE, Larson N, Blaber SI, Giannini C, Blaber M, Vandell AG. Kallikrein 6 is a novel molecular trigger of reactive astrogliosis. Biol Chem. 2012 Apr; 393 (5):355-67
    View PubMed
38. Scarisbrick IA, Epstein B, Cloud BA, Yoon H, Wu J, Renner DN, Blaber SI, Blaber M, Vandell AG, Bryson AL. Functional role of kallikrein 6 in regulating immune cell survival. PLoS One. 2011 Mar 28; 6 (3):e18376
    View PubMed
39. Blaber M, Yoon H, Juliano MA, Scarisbrick IA, Blaber SI. Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis. Biol Chem. 2010 Apr; 391(4):311-20.
    View PubMed
40. Yoon H, Blaber SI, Debela M, Goettig P, Scarisbrick IA, Blaber M. A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15. Biol Chem. 2009 Apr; 390(4):373-7.
    View PubMed
41. Vandell AG, Larson N, Laxmikanthan G, Panos M, Blaber SI, Blaber M, Scarisbrick IA. Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines. J Neurochem. 2008 Nov; 107 (3):855-70 Epub 2008 Sept 06
    View PubMed
42. Yoon H, Blaber SI, Evans DM, Trim J, Juliano MA, Scarisbrick IA, Blaber M. Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis. Protein Sci. 2008 Nov; 17(11):1998-2007. Epub 2008 Aug 12.
    View PubMed
43. Scarisbrick IA, Linbo R, Vandell AG, Keegan M, Blaber SI, Blaber M, Sneve D, Lucchinetti CF, Rodriguez M, Diamandis EP. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem. 2008 Jun; 389 (6):739-45
    View PubMed
44. Scarisbrick IA. The multiple sclerosis degradome: enzymatic cascades in development and progression of central nervous system inflammatory disease. Curr Top Microbiol Immunol. 2008; 318:133-75
    View PubMed
45. Yoon H, Laxmikanthan G, Lee J, Blaber SI, Rodriguez A, Kogot JM, Scarisbrick IA, Blaber M. Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J Biol Chem. 2007 Nov 2; 282(44):31852-64. Epub 2007 Sep 06.
    View PubMed
46. Blaber SI, Yoon H, Scarisbrick IA, Juliano MA, Blaber M. The autolytic regulation of human kallikrein-related peptidase 6. Biochemistry. 2007 May 1; 46(17):5209-17. Epub 2007 Apr 07.
    View PubMed
47. Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, Diamandis EP, Hollenberg MD. Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem. 2006 Oct 27; 281(43):32095-112. Epub 2006 Aug 02.
    View PubMed
48. Scarisbrick IA, Blaber SI, Tingling JT, Rodriguez M, Blaber M, Christophi GP. Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J Neuroimmunol. 2006 Sep; 178(1-2):167-76. Epub 2006 Jul 07.
    View PubMed
49. Scarisbrick IA, Sabharwal P, Cruz H, Larsen N, Vandell AG, Blaber SI, Ameenuddin S, Papke LM, Fehlings MG, Reeves RK, Blaber M, Windebank AJ, Rodriguez M, Rodriguez M. Dynamic role of kallikrein 6 in traumatic spinal cord injury. Eur J Neurosci. 2006 Sep; 24 (5):1457-69
    View PubMed
50. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergnolle N, Tea I, Blaber M, Blaber SI, Scarisbrick I, Diamandis EP, Hollenberg MD. Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol Chem. 2006 Jun; 387(6):817-24.
    View PubMed
51. Angelo PF, Lima AR, Alves FM, Blaber SI, Scarisbrick IA, Blaber M, Juliano L, Juliano MA. Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects. J Biol Chem. 2006 Feb 10; 281(6):3116-26. Epub 2005 Dec 01.
    View PubMed
52. Laxmikanthan G, Blaber SI, Bernett MJ, Scarisbrick IA, Juliano MA, Blaber M. 1.70 A X-ray structure of human apo kallikrein 1: structural changes upon peptide inhibitor/substrate binding. Proteins. 2005 Mar 1; 58(4):802-14.
    View PubMed
53. Christophi GP, Isackson PJ, Blaber S, Blaber M, Rodriguez M, Scarisbrick IA. Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J Neurochem. 2004 Dec; 91(6):1439-49.
    View PubMed
54. Blaber SI, Ciric B, Christophi GP, Bernett MJ, Blaber M, Rodriguez M, Scarisbrick IA. Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. FASEB J. 2004 May; 18(7):920-2. Epub 2004 Mar 19.
    View PubMed
55. Scarisbrick IA, Rodriguez M. Hit-Hit and hit-Run: viruses in the playing field of multiple sclerosis. Curr Neurol Neurosci Rep. 2003 May; 3 (3):265-71
    View PubMed
56. Bernett MJ, Blaber SI, Scarisbrick IA, Dhanarajan P, Thompson SM, Blaber M. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem. 2002 Jul 5; 277(27):24562-70. Epub 2002 Apr 30
    View PubMed
57. Scarisbrick IA, Blaber SI, Lucchinetti CF, Genain CP, Blaber M, Rodriguez M, Rodriguez M. Activity of a newly identified serine protease in CNS demyelination. Brain. 2002 Jun; 125 (Pt 6):1283-96
    View PubMed
58. Blaber SI, Scarisbrick IA, Bernett MJ, Dhanarajan P, Seavy MA, Jin Y, Schwartz MA, Rodriguez M, Blaber M. Enzymatic properties of rat myelencephalon-specific protease. Biochemistry. 2002 Jan 29; 41(4):1165-73.
    View PubMed
59. Scarisbrick IA, Isackson PJ, Ciric B, Windebank AJ, Rodriguez M. MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J Comp Neurol. 2001 Mar 12; 431 (3):347-61
    View PubMed
60. Scarisbrick IA, Asakura K, Rodriguez M. Neurotrophin-4/5 promotes proliferation of oligodendrocyte-type-2 astrocytes (O-2A). Brain Res Dev Brain Res. 2000 Sep 30; 123 (1):87-90
    View PubMed
61. Scarisbrick IA, Asakura K, Blaber S, Blaber M, Isackson PJ, Bieto T, Rodriguez M, Rodriguez M, Windebank AJ. Preferential expression of myelencephalon-specific protease by oligodendrocytes of the adult rat spinal cord white matter. Glia. 2000 May; 30 (3):219-30
    View PubMed
62. Scarisbrick IA, Isackson PJ, Windebank AJ. Differential expression of brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 in the adult rat spinal cord: regulation by the glutamate receptor agonist kainic acid. J Neurosci. 1999 Sep 15; 19 (18):7757-69
    View PubMed
63. Scarisbrick IA, Towner MD, Isackson PJ. "Nervous system-specific expression of a novel serine protease: Regulation in the adult rat spinal cord by excitotoxic injury": Correction The Journal of Neuroscience. 1998 Mar; 18: (6).
    
64. Scarisbrick IA, Towner MD, Isackson PJ. Nervous system-specific expression of a novel serine protease: regulation in the adult rat spinal cord by excitotoxic injury. J Neurosci. 1997 Nov 1; 17 (21):8156-68
    View PubMed
65. Scarisbrick IA, Jones EG, Isackson PJ. Coexpression of mRNAs for NGF, BDNF, and NT-3 in the cardiovascular system of the pre- and postnatal rat. J Neurosci. 1993 Mar; 13(3):875-93.
    View PubMed
66. Scarisbrick IA, Jones EG. NCAM immunoreactivity during major developmental events in the rat maxillary nerve-whisker system. Brain Res Dev Brain Res. 1993 Jan 15; 71(1):121-35.
    View PubMed
67. Scarisbrick IA, Hrycyshyn AW, Haase P. Effects of self- and cross-reinnervation on the numbers of motoneurons regenerating to forearm muscles in young and adult rats. Brain Res Bull. 1992 Feb; 28(2):209-18.
    View PubMed
68. Scarisbrick IA, Haase P, Hrycyshyn AW. The arrangement of forearm motoneurons in young and adult rats and the possibility of naturally occurring motoneuron death. J Anat. 1990 Aug; 171:57-67.
    View PubMed